NL-OMON47320已完成不适用
A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of TAS-119 in Patients with Advanced Solid Tumours - TO-TAS-119-102
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •The Subject:
- •1. Is a male or female, * 18 years of age, who has provided written informed consent.
- •2. Has histologically or cytologically confirmed advanced, unresectable and/or metastatic solid tumour(s) for which the patient has no available therapy likely to provide clinical benefit;
- •3. Has Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 on Cycle 1, Day 1.
- •4. Must have an archival formalin-fixed, paraffin-embedded (FFPE) tumour sample available, to be provided to the Sponsor upon request.
- •5. In the Expansion Phase: patients should be willing to undergo core tumour biopsy procedure (on or before Day 1, Cycle 1) and on Day 4, Cycle 1 (6 hours ± 2 hours postdose) if, in the judgment of the investigator, it is considered clinically safe and appropriate to do so. This requirement is optional but preferred for patients in Dose Escalation.
- •6. Should be willing to undergo pretreatment sampling of non-tumour surrogate tissue for pharmacodynamic assessments (ie, a 3 mm punch biopsy of skin from either the arm or the back of the scalp) if, in the judgment of the investigator, it is considered clinically safe and appropriate to do so.
- •7. Is able to take medications orally (eg, no feeding tube).
- •8. Has adequate organ function as defined by the following criteria:
- •i. Aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT/serum glutamic pyruvic transaminase [SGPT]) * 3.0 × upper limit of normal (ULN).
- •ii. Total serum bilirubin within normal limits. Patients with Gilbert's Syndrome could be considered eligible if bilirubin is * 1 × ULN, but serum bilirubin ratio of unconjugated/conjugated is greater than 1 or most of serum bilirubin fraction should be unconjugated.
- •iii. Absolute neutrophil count of * 1,500/mm3 (ie, * 1.5 × 109/L by International Units [IU]).
- •iv. Platelet count * 100,000/mm3 (IU: * 100 × 109/L). Transfusion of whole blood, platelets, or red blood cells (RBCs) is prohibited within 1 month prior to initiation of study treatment.
- •v. Hemoglobin value of * 9.0 g/dL.
- •vi. Total serum creatinine of * 1.5 × ULN.
- •vii. Serum albumin * 2.5 g/dL.
- •9. Women of childbearing potential must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females and must agree to use effective birth control during the study [prior to the first dose and for 6 months after the last dose if conception is possible during this interval] if conception is possible during this interval. Female patients are considered to not be of childbearing potential if they have a history of tubal ligation or hysterectomy or are post-menopausal with a minimum of 1 year without menses.
- •10. Is willing and able to comply with scheduled visits and study procedures.
排除标准
- •The Subject:
- •1. Has received prior treatment with TAS-119.
- •2. Has received treatment with any of the following within the specified time frame prior to study drug administration:
- •a) Major surgery within prior 4 weeks (the surgical incision should be fully healed prior to study drug administration).
- •b) Radiotherapy for extended field within 4 weeks prior to study drug administration or limited field radiotherapy within 2 weeks prior to study drug administration.
- •c) Previous cytotoxic chemotherapy for advanced or metastatic solid tumors consisting of more than 5 different regimens in total.
- •d) Any anticancer therapy within 3 weeks prior to study drug administration (mitomycin within prior 5 weeks). Patients with metastatic prostate cancer receiving luteinizing hormone-releasing (LHRH) analogs will be eligible.
- •e) Any investigational agent received either concurrently or within the last 30 days.
- •f) Transfusion of whole blood, platelets, or packed red blood cells is prohibited within 1 month prior to study treatment.
- •3. Has a serious illness or medical condition(s) including, but not limited to, the following:
- •a) Known brain metastasis unless the lesions have been previously treated with surgery or radiotherapy, and have been stable off steroids for * 2 months.
- •b) Known leptomeningeal metastasis.
- •c) Known acute systemic infection.
- •d) Myocardial infarction, severe/unstable angina, symptomatic
- •congestive heart failure (New York Heart Association [NYHA] class III or IV within the previous 6 months ( if > 6 months cardiac function must be within normal limits [ie, known ejection fraction * 50%] and the patient must be free of cardiac-related symptoms).
- •e) Chronic nausea, vomiting, or diarrhoea, considered to be clinically significant in the opinion of the Investigator.
- •f) Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or a history of serum positivity to hepatitis B or C.
- •g) Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study.
- •4. Has known hypersensitivity to TAS-119 or any of its components;
- •5. Is pregnant or lactating female.
研究者
相似试验
进行中（未招募）
不适用
A phase 1 dose-escalating study for CT-P27 on its own and in combination with TamifluDiseases of th respiratory systemKCT0001617Celltrion36
已完成
1 期
Phase I Study of TAS-120 in Patients with Advanced Solid TumorsJPRN-jRCT2080222501Taiho Pharmaceutical Co., Ltd.142
已完成
1 期
A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, AND EFFICACY STUDY OF TAS-117 IN PATIENTS WITH ADVANCED SOLID TUMORSPatients with advanced solid tumors, ovarian clear cell carcinoma and endometrial cancer.JPRN-jRCT2080222728Taiho Pharmaceutical Co., Ltd.168
未知
1 期
A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, AND EFFICACY STUDY OF TAS-121 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)SCLCJPRN-jRCT2080222600Taiho Pharmaceutical Co., Ltd.
进行中（未招募）
1 期
A study of an oral anticoagulant (Edoxaban) in childreEUCTR2015-005732-18-ITDaiichi Sankyo , Inc.66